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Objectives: This systematic review and meta-analysis evaluated the outcomes of patients with osteoporosis-re-
lated fractures managed through fracture liaison services (FLS) programs.
Methods:Medline, PubMed, EMBASE, and the Cochrane Library were searched (January 2000–February 2017 in-
clusive) using the keywords ‘osteoporosis’, ‘fractures’, ‘liaison’, and ‘service’ to identify randomised controlled tri-
als and observational studies of patients aged ≥50 years with osteoporosis-related fractures in hospital, clinic,
community, or home-based settings who were managed using FLS. Risk of bias was assessed at outcome level.
Meta-analysis followed a random-effects and ﬁxed-effects model. Outcomes of interest were incidence of bone
mineral density (BMD) testing, treatment initiation, adherence, re-fractures, and mortality due to osteoporosis
treatment.
Results: A total of 159 publications were identiﬁed for the systematic literature review; 74 controlled studies (16
RCTs; 58 observational studies)were included in themeta-analysis. Overall, 41 of 58observational studies and12
of 16 RCTs were considered of high quality. Compared with patients receiving usual care (or those in the control
arm), patients receiving care from an FLS program had higher rates of BMD testing (48.0% vs 23.5%) and treat-
ment initiation (38.0% vs 17.2%) and greater adherence (57.0% vs 34.1%). Unweighted average rates of re-fracture
were 13.4% among patients in the control arm and 6.4% in the FLS arm. Unweighted average rates of mortality
were 15.8% in the control arm and 10.4% in the FLS arm. Meta-analysis revealed signiﬁcant FLS-associated im-
provements in all outcomes versus non-FLS controls, with BMD testing increased by 24 percentage points
(95% conﬁdence interval [CI] 0.18–0.29), 20 percentage points for treatment rates (95% CI 0.16–0.25), and 22per-
centage points for adherence (95% CI 0.13–0.31) and absolute risk of re-fracture reduced by ﬁve percentage
points (95% CI –0.08 to−0.03) and mortality reduced by three percentage points (95% CI –0.05 to−0.01).
Conclusion: FLS programs improved outcomes of osteoporosis-related fractures, with signiﬁcant increases in
BMD testing, treatment initiation, and adherence to treatment and reductions in re-fracture incidence and
mortality.
© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).
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1. Introduction
Osteoporosis is characterised by a reduction in bone mass and
strength, predisposing patients to an increased risk of fragility fractures
[1]. The condition is asymptomatic and therefore its ﬁrst clinical mani-
festation is often a low-trauma (fragility) fracture. Fragility fractures
cause signiﬁcant morbidity and mortality, and therefore are a consider-
able public health burden [2]. The National Osteoporosis Foundation es-
timated that 10.2 million Americans had osteoporosis in 2010, and that
1 in 2 women and 1 in 5 men will experience an osteoporotic-related
fracture during their lifetime [3]. Furthermore, a previous low-trauma
fracture, at any site, increases the risk of a subsequent fracture by ap-
proximately two fold in women and men [4,5].
Fracture liaison services (FLS) are coordinator-based models of sec-
ondary fracture prevention services with a broad remit. They are de-
signed to identify patients who are at increased risk of secondary
fractures and, following a comprehensive assessment, ensure that pa-
tients initiate appropriate treatment via improved care coordination
and communication [6–8]. Indeed, the provision of FLS services is rec-
ommended in guidelines for the prophylaxis of secondary bone frac-
tures issued by the American Society for Bone and Mineral Research
(ASBMR) [9] and European League Against Rheumatism (EULAR)/Euro-
pean Federation of National Associations of Orthopaedics and
Traumatology (EFFORT) [10]. FLS have made signiﬁcant contributions
towards improving bonemineral density (BMD) testing rates and treat-
ment initiation rates after MTF when FLS have adopted a fully coordi-
nated intensive approach to patient care, as shown in a systematic
literature review (SLR) and meta-analysis performed in 2012 covering
publications in 1996–2011 [11]. However, it is acknowledged that treat-
ment gaps remain [11], and pharmacological prevention remains sub-
optimal. In 2013, the International Osteoporosis Foundation (IOF)
initiated the promotion of FLS programs, continually being imple-
mented worldwide, but their outcomes show wide variability in the
literature.
The present SLR and meta-analysis aimed to update, critically re-
evaluate, and quantify the available evidence on the incidence of BMD
testing, treatment initiation, adherence, re-fractures, and rates of mor-
tality associated with FLS in patients with osteoporosis.
2. Methods
2.1. Study identiﬁcation
A systematic search of the literature using Medline, PubMed, and
EMBASE databases and the Cochrane Librarywas conducted for publica-
tions (January 2000–February 2017 inclusive) using the key words: ‘os-
teoporosis’ AND ‘fractures’ AND ‘liaison’ AND ‘service’. The detailed
search strategy is presented in Supplementary Table 1. Other local da-
tabases, websites, and grey literature sourceswere also searched for rel-
evant articles. The SLR adheres to the methodology of the Cochrane
Collaboration.
2.2. Study selection and data abstraction
Inclusion criteria for studies were: conducted in patients aged
≥50 years, with all types of osteoporosis-related fractures; randomised
or non-randomised phase 1–4 trials, retrospective or prospective obser-
vational studies. Excluded were studies related to primary fracture pre-
vention or other bone-associated disease (e.g. osteoarthritis);
publication types of narrative reviews, systematic reviews, meta-analy-
ses, opinion articles, editorials, case reports, letters, and publications in
languages other than English. Two independent reviewers selected
studies by screening ﬁrst the title and abstract followed by full-text ar-
ticles. Discrepancy between the two reviewers was resolved by consen-
sus or by a third independent reviewer, when required. Data extraction
used the Population, Intervention, Comparison, Outcomes, Setting
(PICOS) criteria and included general information about the article
(e.g. authors, publication year), study characteristics (e.g. design, sam-
ple size), patient characteristics (e.g. fracture type, osteoporosis dura-
tion), and outcomes (BMD testing, treatment initiation, adherence,
persistence, rates of re-fracture, and mortality).
Data synthesis and ﬁndings were reported according to the Pre-
ferred Reporting Items for Systematic Reviews and Meta-Analysis
(PRISMA) statement. Quality assessments of the eligible studymethod-
ologies were performed using the Newcastle–Ottawa scale for non-
randomised studies and the Cochrane Collaboration's Risk of Bias Tool
for randomised controlled trials (RCTs).
2.3. Meta-analysis
All studies included in the SLR were reviewed for inclusion in the
meta-analysis. The inclusion criteria were based on PICOS elements:
population (aged ≥50 years with osteoporosis-related fractures); inter-
ventions (FLS); comparison (FLS vs non-FLS care), outcomes (measure-
ment of BMD at any site, treatment initiation, adherence to treatment,
incidence of re-fractures, and rates of all-cause mortality); and study
design (RCTs, observational studies). Studies with no control groups
or denominator data, or with pre-post intervention design were ex-
cluded, except for adherence outcomes.
Data were extracted for each outcome, including study design, study
duration, and number of participants with reported outcome/total
number of participants in the respective arms. Adjusted and unadjusted
estimates of relative risk, odds ratio, hazard ratio, and confounderswere
extracted. A hierarchicalmeta-analysiswas performed on the intention-
to-treat population for each outcome,ﬁrst on all studies, then separately
for RCTs and controlled observational studies. Meta-analyses were con-
ducted when ≥2 studies could be pooled, with consideration of clinical
and statistical heterogeneity. Random-effect meta-analysis was used
as the primarymodel. Sensitivity analyseswere performed for inﬂuence
of study design and ﬁxed-effect model on outcomes. Statistical hetero-
geneity was estimated using the I2 statistic. Publication bias was mea-
sured by the Eggers test when ≥10 studies were included and
analysed using funnel plots.
Summary statistics of population characteristics for continuous var-
iables included number and percentage of discrete variables, mean, and
standard deviation. Statistical signiﬁcance was considered at α= 0.05
and conﬁdence intervals (CI) were set at 95%.
All meta-analysis were carried out in StatsDirect [12].
3. Results
A total of 6608 records from databases and 628 from other sources
were retrieved; 1573 were duplicates. Of 5663 unique citations identi-
ﬁed, 5108 did not meet the selection criteria, leaving 555 relevant pub-
lications, which were evaluated as full-text articles. A total of 396
publications were excluded from the SLR for reasons including dupli-
cates, language, publication type, population not of interest, and irrele-
vant outcome. The remaining 159 publications were included in the
qualitative analysis. This consisted of 141 full-text articles, 16 confer-
ence abstracts, and 2 reports. The 159 studies contributed 316 osteopo-
rosis outcomes.
The meta-analysis included studies with control groups or denomi-
nator data, with the exception of adherence outcomes. This provided a
total of 74 publications, which included 16 RCTs and 58 observational
studies (Fig. 1). These 74 studies contributed a total of 141 osteoporosis
outcomes. Due to the low number of studies reporting on persistence,
this outcome was excluded from quantitative analysis resulting in a
total of 73 papers contributing 134 osteoporosis outcomes. A total of
37 RCTs and controlled observational studies reported on BMD testing,
46 studies on treatment rates, and 25 studies including RCTs, controlled,
and uncontrolled observational studies reported on adherence to treat-
ment. A total of 11 RCTs and controlled observational studies reported
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on re-fracture rates, and 15 on mortality. Outcomes quantiﬁed in the
meta-analysis are reported in Table 1. For each outcome, largely similar
results were obtained in the ﬁxed-effects model (Supplementary Table
2).
3.1. BMD testing
BMD testing, along with the identiﬁcation of at-risk patients, is a
major part of any primary or secondary fracture prevention program.
The meta-analysis included 37 studies reporting on BMD testing (13
RCTs and 24 controlled observational studies; Supplementary Table
3). Unweighted average rates of BMD testing were 23.5% of patients in
the control arm and 48.0% in the FLS arm, with a follow-up period rang-
ing from 3 to 26 months. Furthermore, the meta-analysis showed a sig-
niﬁcant increase in BMD testing rates with FLS interventions by 24
percentage points compared with controls (absolute risk increase
[ARI] 0.24, 95% CI 0.18 to 0.29; I2 = 96.1%; NNT = 4) (Fig. 2; Table 1).
A similar increase was also shown in separate analyses of RCTs and of
controlled observational studies (Table 1).
3.2. Treatment initiation rates
Most of the studies indicated that, across the globe, FLS have led to
dramatic increases in the rates of clinical management among patients
who have experienced fragility fractures (Supplementary Table 4).
The meta-analysis included 46 studies reporting treatment rates (14
RCTs and 32 controlled observational studies). Unweighted average
rates of treatment initiation were 17.2% of patients in the control arm
and 38.0% in the FLS arm,with a follow-up range of 3–72months across
the studies. The meta-analysis conﬁrmed that FLS interventions were
associated with signiﬁcant higher treatment rates by 20 percentage
points compared with controls (ARI 0.20, 95% CI 0.16 to 0.25; I2 =
96%; NNT= 5) (Fig. 3; Table 1). Results were similar in separate analy-
ses of RCTs alone and controlled observational studies alone (Table 1).
3.3. Adherence to treatment
Adherence to osteoporosis medication was reported in 25 stud-
ies that were included in the meta-analysis (two RCTs, seven
controlled, and 16 uncontrolled observational studies) (Supple-
mentary Table 5). In the nine controlled studies, unweighted aver-
age rates of adherence were 34.1% in the control arm and 57.0% in
the FLS arm, with a follow-up range 3–48 months across the stud-
ies. The meta-analysis for pooled RCTs and controlled observa-
tional studies showed FLS interventions signiﬁcantly increase
adherence by 22 percentage points compared with controls (ARI
0.22; 95% CI 0.13 to 0.31; I2 = 75.8%; NNT = 5) (Fig. 4; Table 1).
Similarly, analysis of only RCTs indicated an increase (ARI 0.14;
95% CI –0.06 to 0.35; I2 = 69.6%) as did analysis of only controlled
observational studies (ARI 0.24, 95% CI 0.13 to 0.35; I2 = 79.8%;
NNT = 4) (Table 1). Meta-analysis of the uncontrolled studies re-
ported a 75% proportion for adherence in patients enrolled in FLS
programs (ARI 0.75; 95% CI 0.69 to 0.80; I2 = 90.7%).
3.4. Re-fracture
Eleven studies provideddata on re-fracture rates (twoRCTs andnine
controlled observational studies) andwere included in the meta-analy-
sis (Supplementary Table 6), providing data on 19,519 patients with
osteoporosis who experienced a fragility fracture. Unweighted average
rates of re-fracture were 13.4% of patients in the control arm and 6.4%
in the FLS arm, with a follow-up range of 6–72 months. Meta-analysis
indicated that FLS interventions signiﬁcantly reduced the risk of re-frac-
ture by ﬁve percentage points comparedwith controls (absolute risk re-
duction [ARR] –0.05, 95% CI –0.08 to−0.03; I2 = 91%; numbers needed
to treat [NNT] = 20) (Fig. 5; Table 1). Results were similar in
separate analyses of RCTs only and controlled observational studies
only (Table 1).
Fig. 1. PRISMA ﬂow diagram. MA, meta-analysis; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analysis; SLR, systematic literature review.
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3.5. Mortality
Fifteen studies provided data on mortality (four RCTs and 11 con-
trolled observational studies) and were included in the meta-analysis
(Supplementary Table 7). Unweighted average rates of mortality
were 15.8% of patients with fragility fractures in the control arm and
10.4% in the FLS arm, with a follow-up range of 6–72 months. Meta-
analysis revealed that FLS interventions signiﬁcantly reduced the risk
of mortality by three percentage points compared with controls (ARR
–0.03, 95% CI –0.05 to−0.01; I2=81%; NNT=33) (Fig. 6; Table 1). Sep-
arate analyses by RCTs or by controlled observational studies showed
the same trends (Table 1). The quality rating for the controlled observa-
tional studies and RCTs is shown in Supplementary Tables 8 and 9.
4. Discussion
The present SLR and meta-analysis were conducted to identify and
quantify contemporary data from the literature on the impact of FLS
on patient outcomes following an osteoporosis-related fracture. Most
studies indicated that FLS across the globe have led to a tremendous in-
crease in the rates of clinical management and treatment among pa-
tients who experienced fragility fractures, and in turn a reduction of
re-fracture and mortality rates. On the other hand, despite the marked
improvements to services made available to osteoporosis patients
experiencing fragility fractures through FLS, there is still room for im-
provement: the present study found that adherence to treatment re-
mains rather poor and just under half of the patients in the FLS arm
undergo BMD testing.
Speciﬁcally, theﬁndings here showFLS to have been successful in re-
ducing the rates of clinical re-fractures due to bone fragility and of mor-
tality with absolute reductions of ﬁve and three percentage points,
respectively, representing about 30% and 20% reduction and translating
into number needed to treat of 20 and 33 patients who would need to
be enrolled in an FLS program to avoid one re-fracture or death, respec-
tively. This signiﬁcant improvement in patients' outcomes seenwith FLS
is a result of the coordinated efforts of different healthcare professionals,
the patient, and the appropriate patient evaluation. This interdisciplin-
ary approach comprises identiﬁcation and risk assessment of clinical
factors among fragility fracture patients. Analysis of the evidence
supporting the cost-effectiveness of FLS services is currently ongoing
and will be reported separately.
For the present meta-analysis, both random- and ﬁxed-effects
models were considered. The rather conservative random-effects
model was chosen for the primary analysis because it providesmore re-
liable estimates in most cases due to the presence of substantial statisti-
cal heterogeneity. An exception was in the case of re-fracture rate in
RCTs, where ﬁxed effects were deemed appropriate due to the low
number of RCTs available for analysis. Overall results from ﬁxed-effects
analyses were consistent with the outcomes of the random-effects
models.
The ﬁndings of the systematic review and meta-analysis presented
here are consistent with and extend those reported in the opinion
piece by Briot et al. [14] and the meta-analysis by Ganda et al. [11] for
BMD testing and treatment initiation. The present meta-analysis
assessed 74 publications based on searches from 2000 to 2017,
expanding on the 42 publications obtained over the period 1996–2011
thatwere evaluated byGanda and colleagues. Briot et al. provided a nar-
rative reviewof the evidencewithout any quantitative synthesis, in con-
trast to our analysis. Apart from a quantitative synthesis of the evidence
of BMD testing and treatment initiation that has accumulated since
Ganda et al. published their meta-analysis in 2012, we also conducted
additional meta-analysis on re-fracture, mortality, and adherence
rates. We have also conducted sensitivity analyses to examine the ro-
bustness of our results based on study design. We provide ratings on
the quality of the studies to allow readers better to judge the evidence.
Therefore, to date, the present publication is the ﬁrst to have provided
quantitative analyses and outcomes for publications after 2012. In addi-
tion, it is important to note that the present analysis is the ﬁrst publica-
tion, to our knowledge, that quantitatively reports on re-fracture,
mortality, and adherence rates in these populations.
Another differentiating aspect of the present analysis compared
with that of Ganda et al. lies in the inclusion of study types. Ganda et
al. included controlled cross-sectional studies in addition to RCTs and
controlled observational studies, whereas this analysis only included
RCTs and controlled observational studies for all outcomes, butwith un-
controlled and pre–post studies when assessing adherence. Despite
these differences and the signiﬁcant heterogeneity associated with
Table 1
Summary results frommeta-analysis of RCTs and controlled observational studies.a
Outcome Study design Number of
studies
Study/follow-up duration
(months)
Absolute risk difference, 95% CI
(intervention vs control)
Unweighted
averages
(intervention
vs control)
Statistical
heterogeneity (I2), %
NNT
BMD testing RCTs 13 3–13 0.23 (0.16 to 0.29)⁎ – – 90 4
Controlled
observational
24 1–26 0.24 (0.15 to 0.33) – – 96.9 4
Total 37 3–26 0.24 (0.18 to 0.29) 23.5% 48.0% 96.1 4
Treatment
initiation
RCTs 14 3–12 0.14 (0.09 to 0.18)⁎ – – 85.6 7
Controlled
observational
32 3–72 0.22 (0.16 to 0.28) – – 96.4 5
Total 46 3–72 0.20 (0.16 to 0.25)⁎ 17.2% 38.0% 95.8 5
Adherence RCTs 2 6–24 0.14 (−0.06 to 0.35) – – 69.6 –
Controlled
observational
7 3–48 0.24 (0.13 to 0.35) – – 79.8 4
Total 9 6–48 0.22 (0.13 to 0.31)⁎ 34.1% 57.0% 75.8 5
Re-fracture RCTs 2 6 −0.004 (−0.04 to 0.03) – – 0 –
Controlled
observational
9 6–72 −0.06 (−0.09 to−0.03) – – 92.8 –
Total 11 6–72 −0.05 (−0.08 to−0.03)⁎ 13.4% 6.4% 91.1 20
Mortality RCTs 4 6–12 −0.02 (−0.06 to 0.03) – – 75.8 –
Controlled
observational
11 12–72 −0.04 (−0.07 to−0.01) – – 83 25
Total 15 6–72 −0.03 (−0.05 to−0.01)⁎ 15.8% 10.4% 81.2 33
BMD, bone mineral density; CI, conﬁdence interval; n/a, not applicable; NNT, number needed to treat; RCT, randomised controlled trial.
a Random-effects model.
⁎ p ≤ 0.05.
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observational studies, the consistency between the ﬁndings of both
analyses validates our ﬁndings.
FLS is associated with greater adherence to treatment in patients
with osteoporosis with a history of fragility fracture. However, studies
reporting adherence and persistence to treatment remain scarce.
Ganda et al. reported a similar statistically signiﬁcant absolute increase
of 29% in the rates of treatment, which approximates to the ARI of 20%
reported in the analysis. Additional long-term follow-up studies are re-
quired to support the value of FLS in improving adherence rates.
There are a number of inherent limitations in this analysis. Differ-
ences in the baseline characteristics of patients, such as sex, age, and
baseline fracture location, may impact analysis and the generalisability
of the results. Furthermore, there was a signiﬁcant statistical heteroge-
neity of outcome measures due to variability in study design, follow-
Fig. 2. Forest plot of risk difference in BMD testing from RCTs and controlled observational studies.* *Random-effects model. BMD, bonemineral density; RCT, randomised controlled trial.
The follow-up range across studies was 3–26 months.
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up duration, patient characteristics, and other qualitative attributes. Al-
though we did not ﬁnd evidence of publication bias for several of the
analyses, reporting biases cannot be ruled out. To assuage this limitation
and any possible impact on the data and its interpretation, we sepa-
rately analysed only RCTs that were descriptively balanced at baseline.
The ﬁndings for these separate RCT analyses were aligned with the
overall ﬁndings and conclusions that were based on all studies. Thema-
jority of observational studies were non-randomised, which may result
in a considerable selection biaswhile identifying eligible populations i.e.
may have been susceptible to biases such as the healthy user effect and
measured or unmeasured confounding, such as patients able and will-
ing to participate at the FLS are “healthier” than those who are not
able/willing to attend the FLS. This could inﬂuence the data on survival
and re-fracture risk. Furthermore, some studies made some adjust-
ments, and others not. Better-designed RCTs and controlled observa-
tional studies with longer duration of follow-up and reﬁned
methodology may aid the quantiﬁcation of the effectiveness of FLS pro-
grams. In future analyses, if individual patient data were available, po-
tentially reﬁned methodology could include propensity scores or
instrumental variables. Ideally, an RCT should include a double-blind,
randomised design with an adequate control group such as usual care,
and be of sufﬁcient power and duration to detect long-term differences
in outcomes of interest, such as mortality risk. An ideal setting for such
RCTs might be real-world practice, so as to ensure generalisability of
ﬁndings. Another potential confounderwas thewide variation of length
of follow-up in included studies. This is especially problematic because
it is known that the risk of re-fracture is not constant over time
[13,15]. However, since this was a summary meta-analysis we did not
have individual participant data to conduct time-to-event analyses. Fu-
ture studies should prospectively analyse individual participant data. In
addition, therewas noway to control for a consistent implementation of
FLS programs between hospitals and clinics. There is a reliance on hos-
pital-based data, which may lead to an underestimation of re-fracture
rates and mortality outcomes, if some patients present to other hospi-
tals; however, this would apply equally to FLS and non-FLS settings.
The cost of implementing FLS services and the practical implementation
and cost-effectiveness of care in different settings is an important con-
sideration for any healthcare system but was not considered in this
analysis. In addition, most of the studies identiﬁed in our SLR are from
the USA, Europe, and Australia. Because FLS programs have proven
very effective to improve treatment outcomes and reduce medical
costs, it is important that further studies are conducted to address the
evidence gap in other geographic regions, particularly in Asia-Paciﬁc,
where more than half of all hip fractures are expected to occur by
2050 [16]. It is also important to note that within this study the terms
low-trauma fragility fractures and osteoporosis-related fractures are
Fig. 3. Forest plot of risk difference in treatment initiation rates from RCTs and controlled observational studies.* *Random-effects model. RCT, randomised controlled trial. The follow-up
range across studies was 3–72 months.
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used interchangeably. This was accounted for by ensuring that all low-
trauma fragility fractures included for analysis here were osteoporo-
sis-related. However other FLS studies may differentiate the two terms
and therefore other comparisons to the current study must be made
with caution. Also of note, as mentioned earlier, despite the noticeable
improvements to FLS services that have been made available to
Fig. 4. Forest plot of risk difference in adherence rates from RCTs and controlled observational studies.* *Random-effects model. RCT, randomised controlled trial. The follow-up range
across studies was 6–48 months.
Fig. 5. Forest plot of risk difference in re-fracture rates from RCTs and controlled observational studies.* *Random-effects model. RCT, randomised controlled trial. The follow-up range
across studies was 6–72 months.
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osteoporosis patients experiencing fragility fractures, it is clear that the
situationmay be further improved e.g., as shown in the current analysis,
adherence to treatment remains poor and just under half of the patients
included in the FLS arm underwent BMD testing.
Importantly, under the ‘Capture the Fracture’ campaign of the
IOF, many hospitals and clinics all over the world joined the Best
Practice Programme of secondary fracture prevention. The program
was guided by speciﬁc practice guidelines. Thus far, only 54 of over
150 participating institutions worldwide have received a gold star
award from the IOF, with the majority receiving silver stars and a
smaller proportion bronze stars [17]. FLS, in conjunction with such
guidelines, would likely show greater improved outcomes of all the
parameters included in the present review. The results of this
study, therefore, are potentially an underestimation of the total ben-
eﬁts of FLS services.
5. Conclusion
This SLR and meta-analysis suggests that FLS programs have im-
proved the management of osteoporosis-related fractures, resulting in
higher rates of BMD testing, treatment initiation, and adherence, and
signiﬁcant reductions in re-fracture and mortality rates. The evidence
here suggests that, as more FLS programs are developed and improved,
outcomes such as those assessed herein will also improve correspond-
ingly. FLS are clinically effective across a range of important outcomes
in patientswith fractures of osteoporosis, indicating that they play a sig-
niﬁcant role in minimising the burden of disease.
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